Gan & Lee Pharmaceuticals Co Ltd (603087) — Tangible Net Worth Ratio
Gan & Lee Pharmaceuticals Co Ltd (603087) has a Tangible Net Worth Ratio of 82.3% as of March 2026. This metric is calculated by deducting intangible assets (CN¥2.09 Billion) from net assets (CN¥11.83 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See 603087 net asset value for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Gan & Lee Pharmaceuticals Co Ltd Tangible Net Worth Ratio (2013–2025)
This chart shows how Gan & Lee Pharmaceuticals Co Ltd's Tangible Net Worth Ratio has changed across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 82.3%, reflecting net assets of CN¥11.83 Billion with intangible assets of CN¥2.09 Billion CNY. Also explore 603087 net asset momentum to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Gan & Lee Pharmaceuticals Co Ltd (2013–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Gan & Lee Pharmaceuticals Co Ltd from 2013 to 2025, covering 13 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see how much is Gan & Lee Pharmaceuticals Co Ltd worth.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 83.9% | CN¥11.63 Billion | CN¥1.88 Billion | CN¥12.63 Billion | ▼ -5.4 pp |
| 2024 | 89.2% | CN¥11.05 Billion | CN¥1.19 Billion | CN¥12.04 Billion | ▼ -0.6 pp |
| 2023 | 89.8% | CN¥10.74 Billion | CN¥1.09 Billion | CN¥11.72 Billion | ▲ +0.5 pp |
| 2022 | 89.3% | CN¥9.59 Billion | CN¥1.03 Billion | CN¥10.61 Billion | ▼ -2.1 pp |
| 2021 | 91.4% | CN¥10.17 Billion | CN¥872.49 Million | CN¥10.85 Billion | ▲ +0.0 pp |
| 2020 | 91.4% | CN¥8.94 Billion | CN¥769.62 Million | CN¥9.51 Billion | ▲ +2.2 pp |
| 2019 | 89.2% | CN¥5.47 Billion | CN¥591.33 Million | CN¥6.03 Billion | ▼ -0.9 pp |
| 2018 | 90.1% | CN¥4.27 Billion | CN¥422.84 Million | CN¥4.69 Billion | ▼ -3.5 pp |
| 2017 | 93.6% | CN¥3.34 Billion | CN¥214.49 Million | CN¥3.74 Billion | ▲ +1.1 pp |
| 2016 | 92.5% | CN¥2.26 Billion | CN¥170.05 Million | CN¥2.60 Billion | ▲ +3.9 pp |
| 2015 | 88.6% | CN¥1.49 Billion | CN¥169.25 Million | CN¥1.81 Billion | ▲ +5.0 pp |
| 2014 | 83.6% | CN¥1.04 Billion | CN¥170.05 Million | CN¥1.20 Billion | ▲ +6.5 pp |
| 2013 | 77.1% | CN¥733.22 Million | CN¥167.76 Million | CN¥832.55 Million | — |